“The US performed well,” Mock said in an interview.
(Jan 12): Moderna Inc said its US Covid-19 business did better than expected last year, a rare bright spot for the vaccine maker, which has struggled with the decline of people getting its shot.
The number of people in the US getting Covid-19 shots fell 26% in 2025, according to chief financial officer Jamey Mock. The company had predicted this would drop between 20% and 40%. As a result, Moderna generated 2025 revenue of about US$1.9 billion, up US$100 million from the midpoint of its previous guidance and in line with analysts’ expectations.
